Moolec Science S.A. cash flow to debt ratio of -9.90% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Moolec Science S.A.'s free cash flow has decreased 217.33% from $-9.49M last year to $-30.10M, signaling decreasing performance

Moolec Science S.A.'s debt to equity ratio is -3.74, signaling that the company spent its equity and risk bankruptcy.

Moolec Science S.A.'s debt to equity ratio is -3.74, signaling that the company spent its equity and risk bankruptcy.

Moolec Science S.A. has negative EBITDA, making leverage ratio unreliable

Moolec Science S.A.'s interest coverage ratio is -0.25, which means that the company struggles to meet interest obligations, signaling financial risk.

Moolec Science S.A.'s profit margin has increased (-74.30%) in the last year from -129.99% to -33.41%, signaling increasing performance

Moolec Science S.A.'s short-term liabilities of $236.05M exceed its short-term assets of $31.19M, signaling financial risk

Moolec Science S.A.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Moolec Science S.A.'s return on equity of 376.84%, is higher than 15.00%, indicating good performance

Moolec Science S.A.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Moolec Science S.A. had positive net income in only 0 out of 5 years, indicating unstable earnings

Moolec Science S.A. has negative free cash flow, indicating the company is burning cash rather than generating it

Moolec Science S.A. has negative free cash flow, indicating cash burn

Moolec Science S.A.'s yearly earnings has decreased 1.42K% since last year from $-7.31M to $-111.46M, signaling decreasing performance

Moolec Science S.A.'s yearly revenue has increased 5.83K% since last year from $5.63M to $333.61M, signaling increasing performance

ROIC -5.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Moolec Science S.A. has insufficient revenue history to calculate 3-year revenue CAGR.

Moolec Science S.A. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Moolec Science S.A. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Moolec Science S.A. has insufficient data to evaluate this check.

Moolec Science S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Moolec Science S.A. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Moolec Science S.A. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Moolec Science S.A. has insufficient data to evaluate this check.

Moolec Science S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Moolec Science S.A. has negative shareholder equity; price-to-book is not meaningful and the check fails

Moolec Science S.A. has a price-to-sales ratio of 0.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue